Research To Practice | Oncology Videos

Research To Practice
Research To Practice
  • 4.5 (120)
  • Science
  • Weekly

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

  1. 2d ago ·  Video

    Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity

    Featuring an interview with Dr Erica Mayer, including the following topics: Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00) Investigator Survey Results on Risk Assessment and Genomic Assays (20:07) Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30) Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42) Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07) Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44) Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05) Investigator Survey Results on Adjuvant Oral SERDs (43:02) Discussion of Questions from the Community (45:00) CME information and select publications

  2. 3d ago ·  Video

    Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6

    Featuring perspectives from Dr Lindsey Roeker, including the following topics: Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00) Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46) Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37) CME information and select publications

  3. 3d ago ·  Video

    Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5

    Featuring perspectives from Dr Lindsey Roeker, including the following topics: Consensus Approach to optimizing front-line treatment (0:00) Emerging role of sonrotoclax (8:39) Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48) Evolving role of minimal residual disease assessment (19:16) CME information and select publications

  4. 4d ago ·  Video

    Ovarian Cancer — Microlearning Activity 4: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

    Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery and adjuvant carboplatin/paclitaxel — Professor Jonathan A Ledermann (0:00) CME information and select publications

  5. 5d ago ·  Video

    Ovarian Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

    Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00) CME information and select publications

  6. Oct 24 ·  Video

    Prostate Cancer — An Interview with Prof Karim Fizazi

    Featuring an interview with Prof Karim Fizazi, including the following topics: Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00) Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37) Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47) Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43) Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51) Role of intermittent therapy in the treatment of prostate cancer (38:48) Treatment intensification approaches in prostate cancer (41:38) Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25) CME information and select publications

  7. Oct 23 ·  Video

    Prostate Cancer — An Interview with Prof Karim Fizazi (Companion Faculty Lecture)

    Featuring a slide presentation and related discussion from Prof Karim Fizazi, including the following topics: PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy in high-risk localized prostate cancer (0:00) Time to testosterone recovery during treatment suspension in the Phase III EMBARK trial of enzalutamide and leuprolide in nonmetastatic prostate cancer (5:05) Radiographic progression-free survival subgroup analysis in the PSMAddition Phase III trial of 177Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer (6:58) TALAPRO-3: Efficacy of talazoparib and enzalutamide in metastatic hormone-sensitive prostate cancer harboring homologous recombination repair gene alterations (8:16) Phase I/II PETRANHA study of novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer (10:52) Phase II A-DREAM trial of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer responding to androgen receptor pathway inhibitor (13:23) Overall survival by duration of enzalutamide treatment received in the Phase III ARCHES trial (15:21) Efficacy of capivasertib and abiraterone in the Phase III CAPItello-281 trial for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (16:24) Phase I AcTION study of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy (18:16) Phase III PSMAfore trial of 177Lu-PSMA-617 in progressive mCRPC; ongoing Phase III trials of radioligands in mCRPC (19:54) Ongoing Phase III OMAHA-004 trial of CYP11 inhibitor opevesostat versus next-generation hormonal agent switch in patients with mCRPC and 1 prior next-generation hormonal agent (23:14) CME information and select publications

  8. Oct 23 ·  Video

    Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 4

    Featuring perspectives from Prof Susana Banerjee, including the following topics: Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00) Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58) Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21) CME information and select publications

See All (1K)

4.5
out of 5
120 Ratings

About

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Information

More From Research To Practice

You Might Also Like